Although both allosteric and orthosteric mTOR inhibitors have been investigated in numerous diseases of the central nervous system (CNS) including tuberous sclerosis complex3–5, glioblastoma6–9 and alcohol use disorder10–12, systemic inhibition of mTOR is associated with various dose-limiting adverse effects: immune suppression, metabolic disorders and growth inhibition in children13,14. This evidence concerns the gene MTOR and metabolic disease.